Metabolomics is the comprehensive profiling of small molecule metabolites in cells, tissues, or whole organ- isms. Metabolomics has applications in defining predictive biomarkers for incident cardiometabolic diseases and, increasingly, as a blueprint for understanding those diseases’ pathophysiologic mechanisms.
Proteomics as a whole, deals with the large-scale determination of gene and cellular function directly at the protein level. The field is a collection of various technical disciplines, all of which contribute to proteomics. These include cell imaging by light and electron microscopy, array and chip experiments, and genetic readout experiments, as exemplified by the yeast two-hybrid assay. Another powerful proteomic approach focuses on the de novo analysis of proteins or protein populations isolated from cells or tissues.
Cell Metab. 2017, 10;25(1):43-56 and Nature 422, 198–207
Proteomics and Metabolomics assays can generate informative data to help biologists to get an overview of changes in global proteome/metabolome. This information is often very valuable in generating new hypothesis or testing existing ones.
The Proteomics and Metabolomics Core Facility at Weill Cornell Medicine provides high quality services including:
For more information about the assays, please visit our website